Full Press Release Details
THERAPEUTICS announces preliminary Fourth quarter and
full year 2025 results and provides business updates
Net Revenue of Approximately $127 million
Pro Forma Net Revenue of Approximately $400 million
Adjusted EBITDA of Between $77 million and $81 million
and Short-term Investments of Approximately $148 million
NJ - January 8, 2026 - CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and
commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter
2025 and full-year 2025 results, and provides guidance and an update on its business. These include the following key updates:
Joseph Todisco, CorMedix
Therapeutics CEO, commented, "I'm proud to announce our preliminary Q4 and FY 2025 results today, including surpassing our
guidance for 2025. 2025 was a transformational year for CorMedix, as we evolved beyond a single-product company to an organization with
multiple growth drivers and pipeline assets. We closed 2025 in a strong cash position, which we expect to further bolster over the coming
year, providing the Company with financial flexibility to drive value for shareholders. With our new leadership team in place and multiple
near-term pipeline catalysts, I am excited about the long-term potential for CorMedix Therapeutics."
preliminary financial information presented in this press release is based on CorMedix's current expectations and may be adjusted
as a result of, among other things, the completion of our internal review process and the completion of customary annual audit procedures.
Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment
of life-threatening conditions and diseases. CorMedix is commercializing DefenCath (taurolidine
and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous
catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective
products, including MINOCIN (minocycline) for Injection, REZZAYO (rezafungin), VABOMERE
(meropenem and vaborbactam), ORBACTIV (oritavancin), BAXDELA (delafloxacin), and KIMYRSA
(oritavancin), as well as TOPROL-XL (metoprolol succinate).
has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also
intends to develop DefenCath as a catheter lock solution for use in other patient
populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing
Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO
are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section
21E of the Exchange, as amended (the "Exchange Act"), that are subject to risks and uncertainties. Forward-looking statements
are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can,"
"continue," "could," "estimate," "expect," "intend," "may," "will,"
"plan," "project," "seek," "should," "target," "will," "would,"
and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical
facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects should be considered forward-looking
statements including, but not limited to statements regarding financial guidance, sales, revenue and operating expense estimates, expectations
regarding product utilization, product reimbursement rates, synergy estimates and timing, expectations and timing regarding clinical studies
and development and expectations of CorMedix's product pipeline, results of the real-world study, expectations regarding implementation
and perceived benefits of CorMedix's products. Readers are cautioned that actual results may differ materially from projections
or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix's filings
with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC's website
at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements,
and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these
statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.